health
Small Phase 2a Trial Reports Higher Responses With Nivolumab–Visugromab in Bladder Cancer
In the 31-patient exploratory GDFATHER-NEO trial, nivolumab plus visugromab was associated with higher pathological and radiographic response rates than nivolumab plus placebo before bladder surgery. The small, nonrandomized study was not designed to establish long-term benefit.